Subcutaneous Progesterone Supplementation in Patients With Endometriosis
Status:
Unknown status
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The aim of the study protocol will be to compare the efficacy of subcutaneous progesterone
(25 mg / day; Pleyris, IBSA Institut Biochimique SA) with vaginal progesterone (90 mg / day;
Crinone, Merck Serono) administered during the luteal phase in term of pelvic pain reduction
in patients with grade I-II endometriosis and / or endometrioma <4 cm subjected to time
intercourses or COS/IUI cycles.